1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Medicine
  4. Volume 70, 2019
  5. Article

Annual Review of Medicine

Volume 70, 2019

PD-1 Blockade in Early-Stage Lung Cancer

Abstract

Early-stage non–small cell lung cancer is a potentially curable disease, but with relapse rates exceeding 50% with standard treatments, this is a patient population in critical need of therapy innovation. Immunotherapy with immune checkpoint blockade has revolutionized the treatment strategy for advanced lung cancer. However, the role of this therapy in earlier-stage disease is largely unknown. The study of immunotherapy in earlier-stage disease has many advantages, including assessment of pathologic response and incorporation of translational scientific analyses to evaluate antitumor immune responses. Multiple clinical trials are currently under way, with promising early results.

Keyword(s): early stage, neoadjuvant, nivolumab, non–small cell lung cancer, NSCLC, PD-1 immunotherapy, pembrolizumab
Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-050217-025205
2019-01-27
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/med/70/1/annurev-med-050217-025205.html?itemId=/content/journals/10.1146/annurev-med-050217-025205&mimeType=html&fmt=ahah

Literature Cited

  1. 1.  Noone A, Howlader N, Krapcho M et al. 2018. SEER Cancer Statistics Review, 1975–2015 Bethesda, MD: Natl. Cancer Inst.
  2. 2.  Boyd JA, Hubbs JL, Kim DW et al. 2010. Timing of local and distant failure in resected lung cancer: implications for reported rates of local failure. J. Thorac. Oncol. 5:2211–14
     [Google Scholar]
  3. 3.  Walker LS, Sansom DM 2011. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat. Rev. Immunol. 11:12852–63
     [Google Scholar]
  4. 4.  Keir ME, Butte MJ, Freeman GJ, Sharpe AH 2008. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26:677–704
     [Google Scholar]
  5. 5.  Schiller JH, Harrington D, Belani CP et al. 2002. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346:292–98
     [Google Scholar]
  6. 6.  Socinski MA, Bondarenko I, Karaseva NA et al. 2012. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J. Clin. Oncol. 30:172055–62
     [Google Scholar]
  7. 7.  Brahmer J, Reckamp KL, Baas P et al. 2015. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373:2123–35
     [Google Scholar]
  8. 8.  Borghaei H, Paz-Ares L, Horn L et al. 2015. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373:171627–39
     [Google Scholar]
  9. 9.  Herbst RS, Baas P, Kim DW et al. 2016. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:100271540–50
     [Google Scholar]
  10. 10.  Fehrenbacher L, Spira A, Ballinger M et al. 2016. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387:100301837–46
     [Google Scholar]
  11. 11.  Rittmeyer A, Barlesi F, Waterkamp D et al. 2017. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:10066255–65
     [Google Scholar]
  12. 12.  Topalian SL, Hodi FS, Brahmer JR et al. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366:262443–54
     [Google Scholar]
  13. 13.  Lopes G, Wu YL, Kudaba I et al. 2018. Pembrolizumab versus platinum-based chemotherapy as first-line therapy for advanced/metastatic NSCLC with a PD-L1 TPS≥1%: open-label, phase 3 KEYNOTE-042 study Paper presented at ASCO Annu. Meet. June 3 Chicago, IL:
  14. 14.  Reck M, Rodriguez-Abreu D, Robinson AG et al. 2016. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375:191823–33
     [Google Scholar]
  15. 15.  Brahmer JR, Rodriguez-Abreu D, Robinson AG et al. 2017. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced NSCLC with PD-L1 TPS ≥50% Paper presented at World Congr. Lung Cancer Meet. Oct. 18 Yokohama, Jpn.:
  16. 16.  Langer CJ, Gadgeel SM, Borghaei H et al. 2016. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 17:111497–508
     [Google Scholar]
  17. 17.  Gandhi L, Rodriguez-Abreu D, Gadgeel S et al. 2018. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378:222078–92
     [Google Scholar]
  18. 18.  Socinski MA, Jotte RM, Cappuzzo F et al. 2018. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378:242280–301
     [Google Scholar]
  19. 19.  Jotte RM, Cappuzzo F, Vynnychenko I et al. 2018. IMpower131: primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel versus carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC Paper presented at ASCO Annu. Meet. June 4 Chicago, IL:
  20. 20.  Hellmann MD, Ciuleanu TE, Pluzanski A et al. 2018. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 378:222093–104
     [Google Scholar]
  21. 21.  Gettinger S, Horn L, Jackman D et al. 2018. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study. J. Clin. Oncol. 36:171675–84
     [Google Scholar]
  22. 22.  Pignon JP, Tribodet H, Scagliotti GV et al. 2008. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J. Clin. Oncol. 26:213552–59
     [Google Scholar]
  23. 23.  Wakelee HA, Dahlberg SE, Keller SM et al. 2017. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 18:121610–23
     [Google Scholar]
  24. 24.  Goss GD, O'Callaghan C, Lorimer I et al. 2013. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J. Clin. Oncol. 31:273320–26
     [Google Scholar]
  25. 25.  Kelly K, Altorki NK, Eberhardt WE et al. 2015. Adjuvant erlotinib versus placebo in patients with stage IB–IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial. J. Clin. Oncol. 33:344007–14
     [Google Scholar]
  26. 26.  Butts C, Murray N, Maksymiuk A et al. 2005. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol. 23:276674–81
     [Google Scholar]
  27. 27.  Vansteenkiste JF, Cho BC, Vanakesa T et al. 2016. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 17:6822–35
     [Google Scholar]
  28. 28.  Eggermont AM, Chiarion-Sileni V, Grob JJ et al. 2015. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 16:5522–30
     [Google Scholar]
  29. 29.  Weber J, Mandala M, Del Vecchio M et al. 2017. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N. Engl. J. Med. 377:191824–35
     [Google Scholar]
  30. 30.  Auperin A, Le Pechoux C, Rolland E et al. 2010. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J. Clin. Oncol. 28:132181–90
     [Google Scholar]
  31. 31.  Antonia SJ, Villegas A, Daniel D et al. 2017. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med. 377:201919–29
     [Google Scholar]
  32. 32.  Liu J, Blake SJ, Yong MC et al. 2016. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov 6:121382–99
     [Google Scholar]
  33. 33.  Prowell TM, Pazdur R 2012. Pathological complete response and accelerated drug approval in early breast cancer. N. Engl. J. Med. 366:262438–41
     [Google Scholar]
  34. 34.  Rozeman EA, Blank CU, Van Akkooi A et al. 2017. Neoadjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage III melanoma: updated data from the OpACIN trial and first immunological analyses. J. Clin. Oncol. 35:Suppl. 159586 (Abstr.)
    [Google Scholar]
  35. 35.  Schmid P, Park YH, Muñoz-Couselo E et al. 2017. Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173. J. Clin. Oncol. 35:Suppl. 15556 (Abstr.)
    [Google Scholar]
  36. 36.  Nanda R, Liu MC, Yau C et al. 2017. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. J. Clin. Oncol. 35:Suppl. 15506 (Abstr.)
    [Google Scholar]
  37. 37.  Carthon BC, Wolchok JD, Yuan J et al. 2010. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin. Cancer Res. 16:102861–71
     [Google Scholar]
  38. 38.  Chaft JE, Hellmann MD, Velez MJ et al. 2017. Initial experience with lung cancer resection after treatment with T-cell checkpoint inhibitors. Ann. Thorac. Surg. 104:3e217–218
     [Google Scholar]
  39. 39.  Forde PM, Chaft JE, Smith KN et al. 2018. Neoadjuvant PD-1 blockade in resectable lung cancer. N. Engl. J. Med. 378:211976–86
     [Google Scholar]
  40. 40.  Hellmann MD, Chaft JE, William WN Jr. et al. 2014. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol 15:1e42–50
     [Google Scholar]
  41. 41.  Cottrell TR, Thompson ED, Forde PM et al. 2018. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann. Oncol. 29:81853–60
     [Google Scholar]
  42. 42.  McGranahan N, Furness AJ, Rosenthal R et al. 2016. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351:62801463–69
     [Google Scholar]
  43. 43.  Anagnostou V, Smith KN, Forde PM et al. 2017. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov 7:3264–76
     [Google Scholar]
  44. 44.  Danilova L, Anagnostou V, Caushi JX et al. 2018. The mutation-associated neoantigen functional expansion of specific T cells (MANAFEST) assay: a sensitive platform for monitoring antitumor immunity. Cancer Immunol. Res. 6:8888–99
     [Google Scholar]
  45. 45.  Shu CA, Grigg C, Chiuzan C et al. 2018. Neoadjuvant atezolizumab + chemotherapy in patients with resectable non-small-cell lung cancer Paper presented at ASCO Annu. Meet. June 3 Chicago, IL:
  46. 46.  Rothschild S, Zippelius A, Savic S et al. 2018. SAKK 16/14: anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—a multicenter single-arm phase II trial Paper presented at ASCO Annu. Meet. June 3 Chicago, IL:
  47. 47.  Provencio-Pulla M, Nadal-Alforja E, Cobo M et al. 2018. Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): a phase II multicenter exploratory study—NADIM study-SLCG Paper presented at ASCO Annu. Meet. June 3 Chicago, IL:
  48. 48.  Rusch V, Chaft JE, Johnson B et al. 2018. Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): initial results from a multicenter study (LCMC3) Paper presented at ASCO Annu. Meet. June 3 Chicago, IL:
  49. 49.  Gong X, Li X, Jiang T et al. 2017. Combined radiotherapy and anti-PD-L1 antibody synergistically enhances antitumor effect in non-small cell lung cancer. J. Thorac. Oncol. 12:71085–97
     [Google Scholar]
  50. 50.  Shaverdian N, Lisberg AE, Bornazyan K et al. 2017. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 18:7895–903
     [Google Scholar]
  51. 51.  Takamori S, Toyokawa G, Takada K et al. 2018. Combination therapy of radiotherapy and anti-PD-1/PD-L1 treatment in non-small-cell lung cancer: a mini-review. Clin. Lung Cancer 19:112–16
     [Google Scholar]
/content/journals/10.1146/annurev-med-050217-025205
Loading
PD-1 Blockade in Early-Stage Lung Cancer
Annual Review of Medicine 70, 425 (2019); https://doi.org/10.1146/annurev-med-050217-025205
/content/journals/10.1146/annurev-med-050217-025205
/content/journals/10.1146/annurev-med-050217-025205
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error